Ivermectin is reportedly experiencing a resurgence in use among cancer patients. The circumstances surrounding this comeback are unclear. Meanwhile, a high-ranking official at the FDA, who oversaw vaccines, is departing the agency for the second time, though the connection between this event and ivermectin's use is not specified.